Item 1.01 Entry into a Material Definitive Agreement.
Agreement and Plan of Merger
On
Upon completion of the Merger, each share of KindredBio common stock that is
issued and outstanding immediately prior to the effective time of the Merger
(the "Effective Time") (other than certain excluded shares as described in the
Merger Agreement) will automatically be converted into the right to receive
In addition, at the Effective Time, (i) each share of KindredBio common stock subject to vesting, repurchase or other lapse restriction that is outstanding immediately prior to the Effective Time will fully vest (to the extent such stock would not otherwise vest) and be cancelled and converted automatically into the right to receive the Merger Consideration; (ii) each option to purchase shares of KindredBio common stock (other than rights to purchase shares of KindredBio common stock under the KindredBio employee stock purchase plan) (each, a "KindredBio Option"), whether vested or unvested and whether subject to time-based or performance-based vesting, that is outstanding immediately prior to the Effective Time will become fully vested (to the extent unvested or to the extent such KindredBio Option would not otherwise vest) and be automatically cancelled and converted into the right to receive a payment in cash equal to the product of (a) the excess, if any, of the Merger Consideration over the exercise price per share subject to such KindredBio Option and (b) the total number of shares subject to such KindredBio Option; and (iii) each award of restricted stock units denominated in shares of KindredBio common stock, whether subject to time-based or performance-based vesting, that is outstanding immediately prior to the Effective Time (each, a "KindredBio RSU Award") will become fully vested (to the extent unvested or to the extent such award would not otherwise vest), and be automatically cancelled and converted into the right to receive a payment in cash equal to the product of (A) the total number of shares of KindredBio common stock subject to such KindredBio RSU Award and (B) the Merger Consideration. Any KindredBio Option with a per share exercise price equal to or greater than the Merger Consideration will be cancelled for no consideration.
The completion of the Merger is subject to the satisfaction or waiver of certain
conditions, including (i) requisite approval of the holders of KindredBio common
stock; (ii) the absence of any law or order in
The Merger Agreement contains representations, warranties and covenants of the parties customary for a transaction of this nature. Among other things, until the earlier of the termination of the Merger Agreement and the Effective Time, KindredBio has agreed to operate its business in all respects within 120 days from the date of the Merger Agreement, and in all material respects thereafter, in the ordinary course consistent with past practice and has agreed to certain other operating covenants, as set forth fully in the Merger Agreement. The Merger Agreement also prohibits KindredBio's solicitation of proposals relating to alternative transactions and restricts KindredBio's ability to participate in any discussions or negotiations with, or furnish nonpublic information to, any third party with respect to any such transaction, subject to certain limited exceptions.
The Merger Agreement may be terminated by mutual written consent of Elanco and
KindredBio. The Merger Agreement also permits either party to terminate if (i)
the Merger is not completed by
Elanco also may terminate the Merger Agreement if the board of directors of KindredBio makes an adverse change in its recommendation that KindredBio's stockholders adopt the Merger Agreement or if KindredBio violates or breaches in any material respect the non-solicitation provision of the Merger Agreement in certain circumstances. KindredBio also may terminate the Merger Agreement if it enters into a definitive agreement with respect to a Superior Proposal (as such term is defined in the Merger Agreement), subject to, among other things, payment of the termination fee to Elanco as described below.
KindredBio may be required to pay Elanco a termination fee of
Item 7.01 Regulation FD Disclosure
On
The information contained in the accompanying Exhibits 99.1 and 99.2 is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained in the press release and investor presentation shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events. Support Agreements
Concurrently with the execution and delivery of the Merger Agreement, certain stockholders of KindredBio (each a "Stockholder") entered into a Support Agreement (the "Support Agreements") with Elanco and Merger Sub, pursuant to which each Stockholder agreed, among other things, to vote his, her or its Covered Shares (as defined in the Support Agreement) (i) in favor of the adoption of the Merger Agreement, the Merger and the transactions contemplated thereby and the approval of all agreements related to the Merger, and any proposal to adjourn or postpone the stockholder meeting to a later date if there are not sufficient votes for adoption of the Merger Agreement; (ii) against any Acquisition Proposal (as defined in the Merger Agreement); (iii) against any extraordinary corporate transaction such as a merger agreement or merger (other than the Merger Agreement and the Merger), consolidation, combination, share exchange, reorganization, recapitalization, dissolution, liquidation or winding up of or by KindredBio, or any sale, lease, license or transfer of a material amount of assets of KindredBio; (iv) against any change in or to (a) KindredBio's board of directors that is not recommended by its existing board of directors, (b) the present capitalization or corporate structure of KindredBio, or (c) KindredBio's governing documents that is not consented to by Elanco under the Merger Agreement; and (v) against any proposal, action or agreement that would reasonably be expected to (1) result in a breach of any covenant, representation, warranty or other obligation or agreement of the Stockholder under the Support Agreement or, to the Stockholder's knowledge, of KindredBio under the Merger Agreement or (2) to the Stockholder's knowledge, impede, interfere with or prevent the consummation of the Merger. No Stockholder may propose, commit or agree to take any action inconsistent with any of the foregoing clauses (i), (ii), (iii), (iv) or (v).
Each Stockholder also agreed that, except as provided in the Support Agreement, he, she or it will not (i) offer to transfer, transfer or consent to transfer any of its Covered Shares; (ii) enter into any agreement to transfer his, her or its Covered Shares; (iii) grant any proxy, power-of-attorney or other authorization in respect of its Covered Shares; (iv) deposit or permit the deposit of any of its Covered Shares into a voting trust or enter into a voting agreement or arrangement; (v) create or permit to exist any lien on any of the Covered Shares, or (vi) take any other action that would restrict, limit or interfere with the performance of the Stockholder's obligations under the Support Agreement in any material respect or otherwise make any representation or warranty of the Stockholder untrue or incorrect in any material respect.
Each Stockholder signed the Support Agreement solely in his or her capacity as a stockholder. The Support Agreements do not prohibit any Stockholder from acting (or failing to act) in his or her capacity as an officer or director of KindredBio.
As of
Additional Information
The foregoing description of the principal terms of the Merger Agreement and the form of Support Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, which is attached as Exhibit 2.1 to this report, and the form of Support Agreement, which is attached as Exhibit 99.3 to this report, both of which are incorporated herein by reference.
The Merger Agreement, the form of Support Agreement and the foregoing
description have been included to provide investors and stockholders with
information regarding the terms of these agreements. They are not intended to
provide any other factual information about Elanco, Merger Sub or KindredBio,
their respective businesses, or the actual conduct of their respective
businesses during the period prior to the consummation of the Merger. The
representations, warranties and covenants contained in each of these documents
were or will be made only as of specified dates for the purposes of such
agreement, were (except as expressly set forth therein) solely for the benefit
of the parties to such agreements and may be subject to qualifications and
limitations agreed upon by such parties. In particular, in reviewing the
representations, warranties and covenants contained in the Merger Agreement and
discussed in the foregoing description, it is important to bear in mind that
such representations, warranties and covenants were negotiated with the
principal purpose of allocating risk between the parties, rather than
establishing matters as facts, and are also qualified by a confidential
disclosure letter delivered by KindredBio to Elanco in connection with the
Merger Agreement. Such representations, warranties and covenants may also be
subject to a contractual standard of materiality different from those generally
applicable to stockholders and reports and documents filed with the
Important Information for Investors and Stockholders
This communication does not constitute a solicitation of any vote or approval in
connection with the proposed acquisition of Kindred Biosciences, Inc.
("KindredBio") by
Participants in the Merger Solicitation
Elanco, KindredBio, and certain of their directors, executive officers and
employees may be considered participants in the solicitation of proxies from
KindredBio's stockholders with respect to the proposed transactions. Information
regarding the persons who may, under the
Cautionary Statement Regarding Forward-Looking Statements
Statements included in this report that are not a description of historical facts are forward-looking statements. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" or similar expressions are intended to identify forward-looking statements, and are based on our current beliefs and expectations. These forward-looking statements include, without limitation, statements regarding the proposed acquisition of KindredBio, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that Elanco believes or anticipates will or may occur in the future. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These factors include risks and uncertainties related to, among other things: uncertainties as to the timing of the Merger; the possibility that competing acquisition proposals will be made; the inability to complete the Merger due to the failure to obtain KindredBio's stockholder adoption of the Merger Agreement or the failure to satisfy other conditions to completion of the Merger, including required regulatory approvals; . . .
Item 9.01 Financial Statements and Exhibits
(d) Exhibits Exhibit No. Description 2.1 Agreement and Plan of Merger, dated as ofJune 15, 2021 , by and amongElanco Animal Health Incorporated ,Knight Merger Sub, Inc. and Kindred Biosciences, Inc.* 99.1 Joint Press Release, datedJune 16, 2021 . 99.2 Investor Presentation, datedJune 16, 2021 . 99.3 Form of Support Agreement, amongElanco Animal Health Incorporated ,Knight Merger Sub, Inc. and certain stockholders of Kindred Biosciences, Inc. 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Schedules to the Agreement and Plan of Merger have been omitted pursuant to
Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such
schedules to the
© Edgar Online, source